PLAAT2 functions as a tumor suppressor in GC by recruiting TRIM32 to facilitate cMyc ubiquitination and impair MEK/ERK-driven oncogenic signaling, highlighting the PLAAT2/TRIM32/cMyc axis as a potential therapeutic target. This evidence concerns the gene TRIM32 and gastric cancer.